Understanding MMP12 levels in patients with emphysema

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the correlation between levels of matrix metalloproteinase-12 (MMP12) in sputum and blood with airspace enlargement in patients diagnosed with emphysema. The study utilizes hyperpolarized 129Xe diffusion-weighted MRI to measure alveolar airspace size, providing insights into lung disease progression and treatment response. By analyzing sputum and blood samples, researchers hope to identify potential biomarkers that could lead to targeted therapies for obstructive lung diseases.

Why it matters

Who can join: the full rules

Inclusion Criteria (COPD):

* ≥40 years of age
* Current or ex-smokers with a \>10 pack year smoking history
* Have a post-bronchodilator forced expired volume in 1 second (FEV1)/forced expired vital capacity (FVC) ratio of \<70% and a post-bronchodilator FEV1 value from ≥30% predicted (GOLD 1, 2 and 3), (Global Initiative for Obstructive Lung disease)
* Have a radiologist confirmed pulmonary emphysema diagnosis based on CT

Inclusion criteria for normal controls:

* No clinically significant medical condition or a history of asthma, COPD, cystic fibrosis, or other significant respiratory disorder including significant occupational or environmental exposures with ongoing respiratory symptoms.
* No current or past smoking history
* Have a post-bronchodilator FEV1/FVC ratio of \>70%

Exclusion Criteria:

Any potential subject who meets any of the following criteria will be excluded from participating in the study:

* Patients with other non-COPD airway diseases
* Patients with very severe COPD (FEV1\<30% predicted)
* Patients with an intercurrent exacerbation
* Patients with life expectancy less than 3 months
* Pregnant or breastfeeding
* Undergoing immunomodulatory or biologic treatment
* Use of systemic steroids in the last month
* Hospitalization in the last 12 months due to exacerbation
* Known cardiovascular comorbidity under treatment or with hospitalizations of this cause in the last year
* That they cannot perform spirometry
* Active malignancy
* Realization of lung surgery during the study period
* History of alcohol and drug abuse that prevents compliance with follow-up
* History of bronchial thermoplasty
* Participating in another study concomitantly
* MRI Related: patients who have implanted mechanically, electrically or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, artificial limb, metallic fragments of foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants).

Where it's running

• Firestone Institute for Respiratory Health, St. Joseph's Healthcare
  Hamilton, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Sarah Svenningsen, PhD
• Email: svennins@mcmaster.ca
• Phone: 905-522-1155

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Xenon MRI test for lung changes after Apreo BREATHE airway treatment in emphysema

  This study tests whether hyperpolarized Xenon MRI can show regional ventilation and gas-exchange changes after the Apreo BREATHE airway scaffolds in people with emphysema and air trapping.

  Recruiting Early Phase 1 Apreo Health, Inc. · Birmingham, Alabama and 1 other locations · NCT07896902

• Prediction score for death or lung transplant in emphysema caused by alpha-1 antitrypsin deficiency

  This study tests a new prediction tool to identify people with emphysema due to alpha-1-antitrypsin deficiency who are at high risk of death or needing a lung transplant.

  Recruiting at 4 sites University Hospital, Bordeaux · Bron and 3 other locations · NCT07715617

• Testing CE1226 doses to slow lung disease in adults with alpha-1 antitrypsin deficiency

  This trial tests two active doses of CE1226 to see if they slow lung density decline in adults with AAT deficiency and emphysema over 3 years compared with the standard 60 mg/kg dose.

  Recruiting at 2 sites Phase 4 CSL Behring · Aalborg and 1 other locations · NCT07326592

• Implant to help adults with severe emphysema

  This study will test whether an implantable artificial bronchus can improve breathing and safety in adults with severe COPD/emphysema.

  Recruiting at 4 sites Pulmair Medical, Inc. · San Francisco, California and 3 other locations · NCT07119229

• Endobronchial silicone valve to help breathing in people with severe emphysema

  This trial tests whether placing a silicone valve in the airways of one lung region can improve breathing for people with severe emphysema when added to usual care.

  Recruiting China-Japan Friendship Hospital · Beijing, Beijing Municipality · NCT07097896

• Implantable Artificial Bronchus 50 Flex for adults with severe emphysema

  This tests a small implant called the IAB 50 Flex to see if it is safe and helps adults with severe COPD or emphysema breathe and move more easily.

  Recruiting at 2 sites Pulmair Medical, Inc. · Limoges and 1 other locations · NCT07086339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.